Day 1 │Tuesday 31 January

12.00 – 13.00

Registration

OPENING

13.00 – 13.10

Welcome

Miikka Vikkula │ Chair of the scientific committee

13.10 – 13.25

Vascular anomalies: From genetic discoveries to therapeutic trials

Miikka Vikkula │ VA Cure - de Duve Institute, Brussels, Belgium

13.25 – 13.35

Patient’s perspective

Maria Barea │ VASCAPA

13.35 – 13.40

Patient story

KEYNOTE LECTURE

Chair: Sabine Bailly

13.45 – 14.25

Vascular remodeling in development and disease

Anne Eichmann │ Yale University, New Haven, USA / INSERM, Paris

SESSION VENOUS MALFORMATIONS AND TIE2-PI3K SIGNALING

Chairs: Elisa Boscolo and Laurence Boon

14.25 – 14.45

Angiopoietin-Tie signaling pathway in venous morphogenesis

Lauri Eklund │ VA Cure – Oulu University, Finland

14.45 – 15.00

A Transgenic Mouse Model of Mutant TIE2-Driven Venous Malformation

Lindsay Bischoff │ Cincinnati Children's Hospital Medical Center, USA

15.00 – 15.30

Coffee break

15.30 – 16.00

Insights into the onset and progression of PIK3CA-related vascular malformations

Mariona Graupera│ Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain

16.00 – 16.15

Unraveling PIK3CA-driven pathophysiology of vascular malformations by single cell transcriptomics

Marle Kraft │ VA Cure – Uppsala University, Sweden

16.15 – 16.35

Overview of the current and future targeted treatments in venous malformations

Emmanuel Seront │ Cliniques universitaires Saint-Luc, Brussels, Belgium

16.35 – 16.50

A call for rigorous study of the role of statins in vascular malformations. Preliminary study

Miguel Amore │ Central Military Hospital, Buenos Aires, Argentina

SESSION DEVELOPMENT OF METHODS & MODELS

Chairs: Ryan Hicks and Martina de Bortoli

16.50 – 17.10

High-throughput microphysiological models transforming tissue modelling

Prateek Singh │ VA Cure – Finnadvance, Oulu, Finland

POSTER TEASERS

Chairs: Ryan Hicks and Martina de Bortoli

17.10 – 17.15

Semaphorin 3A and 3F in TIE2-mutated Venous Malformation

Sandra Schrenk │ Cincinnati Children's Hospital Medical Center, USA

17.15 – 17.20

Fibroblasts induce vascular lesion growth – a co-target for treatment?

Johanna Laakkonen │ University of Eastern Finland, Kuopio, Finland

17.20 – 17.25

Sirolimus: friend or enemy of surgeons dealing with vascular anomalies?

Noureddine Hassayoune │ Cliniques universitaires Saint-Luc, Brussels, Belgium

17.25 – 17.30

Releasing an mTORC1 break causes lymphatic hyperplasia and malformation

Antonio Queiro Palou │ VA Cure – Karolinska Institute, Stockholm, Sweden 

17.30 – 17.35

EFNB2 orients ventricular endocardial cells against blood flow

Anusha Sathyanarayanan │ Potsdam University, Germany

Welcome reception in the Brussels City Hall